ImmunityBio Inc
IBRX
Market Cap$5.36B
Close$
$-1.26
116.5% downside
Current Fair Value
116.5% downsideOvervalued by 116.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.36 Billion |
|---|---|
| Enterprise Value | $5.92 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-1.05 |
| Beta | 2.6 |
| Outstanding Shares | 691,567,961 |
| Avg 30 Day Volume | 13,155,642 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -8.92 |
|---|---|
| PEG | -58.4 |
| Price to Sales | - |
| Price to Book Ratio | -3.83 |
| Enterprise Value to Revenue | 19604.38 |
| Enterprise Value to EBIT | -16.91 |
| Enterprise Value to Net Income | -10 |
| Total Debt to Enterprise | 0.12 |
| Debt to Equity | -1.06 |
Revenue Sources
No data
ESG Score
No data
About ImmunityBio Inc
171 employees
CEO: Patrick Soon-Shiong NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer of clinical dose forms ...